COMPANY

Inmune Bio, Inc.

HQ: Boca Raton, FL source · inmunebio.com ↗ · Southeast

Also known as INmune Bio · 9 sources

Location: Boca Raton, FL · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Mental Disorders Neurocognitive Disorders depression Mild Cognitive Impairment COVID-19 MDS-EB Myelodysplastic Syndromes Acute Myeloid Leukemia AML Metastatic Castration-resistant Prostate Cancer mCRPC XPro1595 INKmune INB03

7Trials (company is sponsor)2NIH grants

Timeline

Nov 30, 2023 Trial start Phase 1/Phase 2: Study of INKmune in Patients With mCRPC (CaRe Prostate) source ↗
2023-06 Trial start Phase 2: Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation source ↗
Feb 21, 2023 Trial start Phase 2: An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease source ↗
Feb 28, 2022 Trial start Phase 2: A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation source ↗
Oct 21, 2020 Trial start Phase 2/Phase 3: INB03 for the Treatment of Pulmonary Complications From COVID-19 source ↗
Jun 15, 2020 Trial start I: A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML source ↗
Nov 20, 2019 Trial start Phase 1: A Biomarker-directed Study of XPro1595 in Patients With Alzheimer's source ↗

Clinical trials (lead sponsor) 7

Record	Title	Phase	Status	Start	Primary completion
NCT05318976	A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation	Phase 2	Completed	Feb 28, 2022	May 12, 2025 (actual)
NCT04370236	INB03 for the Treatment of Pulmonary Complications From COVID-19	Phase 2/Phase 3	Terminated	Oct 21, 2020	Oct 13, 2021 (actual)
NCT05933070	A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML	I	Terminated	Jun 15, 2020	Mar 28, 2024 (actual)
NCT05522387	An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease	Phase 2	Terminated	Feb 21, 2023	Jun 5, 2024 (actual)
NCT06056791	Study of INKmune in Patients With mCRPC (CaRe Prostate)	Phase 1/Phase 2	Completed	Nov 30, 2023	Sep 10, 2025 (actual)
NCT05321498	Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation	Phase 2	Withdrawn	2023-06	Oct 26, 2023 (estimated)
NCT03943264	A Biomarker-directed Study of XPro1595 in Patients With Alzheimer's	Phase 1	Completed	Nov 20, 2019	Jun 30, 2021 (actual)

NIH awards 2

Annual award amounts. Total $2.0M.

Aug 24, 2021 NIH award 5R44MH125480-02 FY2021: $1,210,682 awarded for that fiscal year; activity R44 (SBIR); PI BARNUM, CHRISTOPHER J; recipient as written: INMUNE BIO, INC., Boca Raton, FL. Effects of the Next Generation TNF Inh source ↗
Sep 14, 2020 NIH award 1R44MH125480-01 FY2020: $739,739 awarded for that fiscal year; activity R44 (SBIR); PI BARNUM, CHRISTOPHER J; recipient as written: INMUNE BIO, INC., Boca Raton, FL. Effects of the Next Generation TNF Inhib source ↗